Nurexone Biologic Inc
F:J90
Nurexone Biologic Inc
Total Liabilities
Nurexone Biologic Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nurexone Biologic Inc
F:J90
|
Total Liabilities
$698k
|
CAGR 3-Years
-28%
|
CAGR 5-Years
58%
|
CAGR 10-Years
33%
|
|
|
Enerflex Ltd
TSX:EFX
|
Total Liabilities
CA$1.6B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
15%
|
CAGR 10-Years
4%
|
|
|
T
|
TerraVest Industries Inc
TSX:TVK
|
Total Liabilities
CA$1.3B
|
CAGR 3-Years
45%
|
CAGR 5-Years
47%
|
CAGR 10-Years
30%
|
|
|
CES Energy Solutions Corp
TSX:CEU
|
Total Liabilities
CA$815.3m
|
CAGR 3-Years
0%
|
CAGR 5-Years
16%
|
CAGR 10-Years
6%
|
|
|
Secure Energy Services Inc
TSX:SES
|
Total Liabilities
CA$1.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
13%
|
|
|
H
|
HydroGraph Clean Power Inc
CNSX:HG
|
Total Liabilities
$731.1k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
Nurexone Biologic Inc
Glance View
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing a biological extracellular vesicles (EV)-based technology drug platform. The technology drug platform offers treatment for reversing paralysis and improving the life of patients following spinal cord injury using bio-guided exosomes (membrane-bound extracellular vesicles) loaded with modified small interfering RNA (siRNA) sequence. Its technology is used to treat various conditions, such as spinal cord injury, traumatic brain injury, and other brain and neurological indications. The firm also has developed exosome manufacturing process. The company is also focused on exosome research, management of clinical studies and commercialization of the technology for different indications, not limited to the central nervous system.
See Also
What is Nurexone Biologic Inc's Total Liabilities?
Total Liabilities
698k
USD
Based on the financial report for Dec 31, 2024, Nurexone Biologic Inc's Total Liabilities amounts to 698k USD.
What is Nurexone Biologic Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
33%
Over the last year, the Total Liabilities growth was 0%. The average annual Total Liabilities growth rates for Nurexone Biologic Inc have been -28% over the past three years , 58% over the past five years , and 33% over the past ten years .
